Gene:
F5
coagulation factor V (proaccelerin, labile factor)

Dutch Pharmacogenetics Working Group Guideline - hormonal contraceptives for systemic use, F5

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for propafenone based on Factor V Leiden (FVL, or F5) genotype (PMID:21412232). They suggest that in individuals who carry the Factor V Leiden allele and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used.

Phenotype (Genotype) Therapeutic Dose Recommendation Level of Evidence Clinical Relevance
F5 homozygous rs6025 TT Positive (family) history of thrombotic events: avoid estrogen-containing oral contraceptive and select alternative (e.g., copper intrauterine device, progestin-only contraceptive). Negative (family) history of thrombotic events: avoid additional risk factors (e.g., obesity, smoking) Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. Clinical effect (S): long-standing discomfort (> 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR > 6.0; neutropenia 0.5-1.0x10 9/l; leucopenia 1.0-2.0x10 9/l; thrombocytopenia 25-50x10 9/l; severe diarrhea
F5 heterozygous rs6025 CT Positive (family) history of thrombotic events: avoid estrogen-containing oral contraceptive and select alternative (e.g., copper intrauterine device, progestin-only contraceptive). Negative (family) history of thrombotic events: avoid additional risk factors (e.g., obesity, smoking) Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. Clinical effect (S): long-standing discomfort (> 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR > 6.0; neutropenia 0.5-1.0x10 9/l; leucopenia 1.0-2.0x10 9/l; thrombocytopenia 25-50x10 9/l; severe diarrhea
  • *See Methods or PMID: 18253145 for definition of "good" and "moderate" quality.
  • S: statistically significant difference.

PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.

PharmGKB contains no clinical annotations for this gene. To report clinical variants, click here.

PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(build 132) 		Alternate Names ? Drugs ? Alleles ?
(+ chr strand) 		Function ? Amino Acid?
Translation
VIP No Clinical Annotations available No Variant Annotations available
rs6025 F5:Factor V Leiden, c.1601A>G, c.1601G>A, g.167785673T>C, g.21007691T>C, g.41721A>G, g.41721G>A, p.Arg534Gln
T > C
 Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP build 132

Overview

Alternate Names:  OTTHUMP00000032547; OTTHUMP00000032548; activated protein c cofactor; coagulation factor V; coagulation factor V jinjiang A2 domain; factor V; factor V Leiden; labile factor; proaccelerin, labile factor
Alternate Symbols:  FVL; PCCF
PharmGKB Accession Id: PA159

Details

Cytogenetic Location: chr1 : q24.2 - q24.2
GP mRNA Boundary†: chr1 : 169481192 - 169555769
GP Gene Boundary†: chr1 : 169478192 - 169565769
Strand: minus
Product Name: No data available
† The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Common Pathway - (Reactome via Pathway Interaction Database)
  2. Exocytosis of Alpha granule - (Reactome via Pathway Interaction Database)
  3. extrinsic prothrombin activation pathway - (BioCarta via Pathway Interaction Database)
  4. intrinsic prothrombin activation pathway - (BioCarta via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
drotrecogin alfa
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
tamoxifen
Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
estrogens
DG No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
hormonal contraceptives for systemic use

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Sepsis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Thrombosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
venous thromboembolism

Publications related to F5: 84

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al. [Article:21412232@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study. Pharmacogenetics and genomics. 2009. Maitland-van der Zee Anke-Hilse, et al. [Article:19415820@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. Pharmacogenetics and genomics. 2007. Parmeggiani Francesco, et al. [Article:18004208@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Archives of internal medicine. 2006. Ho Wai Khoon, et al. [Article:16606808@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphism in the beta2-adrenergic receptor and lipoprotein lipase genes as risk determinants for idiopathic venous thromboembolism: a multilocus, population-based, prospective genetic analysis. Circulation. 2006. Zee Robert Y L, et al. [Article:16651467@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2006. Sipahi Tansu, et al. [Article:16444434@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health technology assessment (Winchester, England). 2006. Wu O, et al. [Article:16595080@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. Journal of the National Cancer Institute. 2006. Abramson Neil, et al. [Article:16818854@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006. Ye Zheng, et al. [Article:16503463@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. British journal of haematology. 2005. Wu Olivia, et al. [Article:16173967@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005. Straczek Céline, et al. [Article:16301339@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. Journal of thrombosis and haemostasis : JTH. 2005. Brugge J M, et al. [Article:16359508@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke; a journal of cerebral circulation. 2005. Lalouschek Wolfgang, et al. [Article:15947254@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombosis and haemostasis. 2005. Wu Olivia, et al. [Article:16113779@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Annals of internal medicine. 2004. Juul Klaus, et al. [Article:14996674@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Archives of neurology. 2004. Casas Juan P, et al. [Article:15534175@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood. 2004. Kemmeren Jeanet M, et al. [Article:14551147@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood. 2004. Castoldi Elisabetta, et al. [Article:14976057@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Critical care medicine. 2004. Yan S Betty, et al. [Article:15118525@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V Leiden polymorphism modifies sepsis outcome: evidence from animal studies. Critical care medicine. 2004. Weiler Hartmut, et al. [Article:15118524@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V Leiden: a disorder of factor V anticoagulant function. Current opinion in hematology. 2004. Castoldi Elisabetta, et al. [Article:15257017@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Estrogen plus progestin and risk of venous thrombosis. JAMA : the journal of the American Medical Association. 2004. Cushman Mary, et al. [Article:15467059@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. American heart journal. 2003. Kim Robert J, et al. [Article:14660985@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arteriosclerosis, thrombosis, and vascular biology. 2003. Oger Emmanuel, et al. [Article:12869355@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation. Blood. 2003. Castoldi Elisabetta, et al. [Article:12881304@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003. Kerlin Bryce A, et al. [Article:12869495@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C. British journal of haematology. 2003. Mumford A D, et al. [Article:14617013@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. British journal of haematology. 2003. Tanis Bea C, et al. [Article:12877676@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003. Duggan Catherine, et al. [Article:14512389@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Journal of thrombosis and thrombolysis. 2003. Go Alan S, et al. [Article:14574075@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arteriosclerosis, thrombosis, and vascular biology. 2002. Herrington David M, et al. [Article:12067913@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V and thrombotic disease: description of a janus-faced protein. Arteriosclerosis, thrombosis, and vascular biology. 2002. Nicolaes Gerry A F, et al. [Article:11950687@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002. Juul Klaus, et al. [Article:12070000@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2002. Kemmeren J M, et al. [Article:12138364@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. British journal of haematology. 2002. Rosendaal F R, et al. [Article:11886391@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. European heart journal. 2002. Legnani C, et al. [Article:12069454@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002. De Stefano Valerio, et al. [Article:12368166@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis. Medical decision making : an international journal of the Society for Medical Decision Making. 2002. Eckman Mark H, et al. [Article:11958494@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thrombosis and haemostasis. 2002. Kemmeren J M, et al. [Article:11859850@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thrombosis and haemostasis. 2002. Wåhlander K, et al. [Article:12008938@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Annals of internal medicine. 2001. Middeldorp S, et al. [Article:11529695@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency. Blood. 2001. van Wijk R, et al. [Article:11435304@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Population genetics of factor V Leiden in Europe. Blood cells, molecules & diseases. 2001. Lucotte G, et al. [Article:11259157@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. British journal of haematology. 2001. Høibraaten E, et al. [Article:11703344@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. Haematologica. 2001. Santamaría A, et al. [Article:11532625@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease. Journal of thrombosis and thrombolysis. 2001. Irani-Hakime N, et al. [Article:11406725@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of fibrinolysis and prothrombotic risk factors in neonates, infants and children with and without thromboembolism and underlying cardiac disease. a prospective study. Thrombosis research. 2001. Nowak-Göttl U, et al. [Article:11457466@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. American journal of hematology. 2000. Irani-Hakime N, et al. [Article:10936863@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. 2000. Spannagl M, et al. [Article:10943572@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. The New England journal of medicine. 2000. Gerhardt A, et al. [Article:10666427@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis. Thrombosis and haemostasis. 2000. Marchetti M, et al. [Article:11127850@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Coagulation factors II, V, VII, and X, prothrombin gene 20210G-->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arteriosclerosis, thrombosis, and vascular biology. 1999. Redondo M, et al. [Article:10195931@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arteriosclerosis, thrombosis, and vascular biology. 1999. Martinelli I, et al. [Article:10073976@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arteriosclerosis, thrombosis, and vascular biology. 1999. Salomon O, et al. [Article:10073951@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood. 1999. Thorelli E, et al. [Article:10194434@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic risk factors in acute coronary disease. Haemostasis. 1999. Araújo F, et al. [Article:10702702@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Increased frequency of genetic thrombophilia in women with complications of pregnancy. The New England journal of medicine. 1999. Kupferminc M J, et al. [Article:9878639@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. BMJ (Clinical research ed.). 1998. Sarasin F P, et al. [Article:9462312@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation. 1998. Doggen C J, et al. [Article:9531249@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thrombosis and haemostasis. 1998. Andersen B S, et al. [Article:9459317@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. American journal of medical genetics. 1997. Gregg J P, et al. [Article:9415695@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Annals of internal medicine. 1997. Price D T, et al. [Article:9382368@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997. Rosendaal F R, et al. [Article:9108400@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Leiden factor V mutation in four patients with small bowel infarctions. Gastroenterology. 1997. Heresbach D, et al. [Article:9207293@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Prevalence of factor V Leiden mutation in various populations. Genetic epidemiology. 1997. Herrmann F H, et al. [Article:9271712@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut. 1997. Mahmoud A E, et al. [Article:9245936@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA : the journal of the American Medical Association. 1997. Ridker P M, et al. [Article:9109469@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Prevalence of factor V Leiden mutation in non-European populations. Thrombosis and haemostasis. 1997. Pepe G, et al. [Article:9157591@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. British journal of haematology. 1996. Rintelen C, et al. [Article:8639453@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke; a journal of cerebral circulation. 1996. Press R D, et al. [Article:8553401@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. The Biochemical journal. 1996. Aparicio C, et al. [Article:8573079@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thrombosis and haemostasis. 1996. Zöller B, et al. [Article:8815575@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995. Rosendaal F R, et al. [Article:7888671@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. Journal of molecular medicine (Berlin, Germany). 1995. Prohaska W, et al. [Article:8581514@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
World distribution of factor V Leiden. Lancet. 1995. Rees D C, et al. [Article:7475606@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Characterization of the molecular defect in factor VR506Q. The Journal of biological chemistry. 1995. Kalafatis M, et al. [Article:7876154@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. The Journal of biological chemistry. 1995. Camire R M, et al. [Article:7657663@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. The New England journal of medicine. 1995. Ridker P M, et al. [Article:7877648@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994. Vandenbroucke J P, et al. [Article:7968118@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994. Bertina R M, et al. [Article:8164741@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The mechanism of inactivation of human factor V and human factor Va by activated protein C. The Journal of biological chemistry. 1994. Kalafatis M, et al. [Article:7989361@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Localization of the gene encoding human factor V to chromosome 1q21-25. Genomics. 1988. Wang H, et al. [Article:3220473@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats. Biochemistry. 1987. Kane W H, et al. [Article:2827731@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Complete cDNA and derived amino acid sequence of human factor V. Proceedings of the National Academy of Sciences of the United States of America. 1987. Jenny R J, et al. [Article:3110773@PubMed]

LinkOuts

Entrez Gene:
2153
OMIM:
188055
227400
600880
601367
612309
UCSC Genome Browser:
NM_000130
RefSeq RNA:
NM_000130
RefSeq Protein:
NP_000121
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NG_011806
NT_004487
NW_001838533
NW_926128
UniProtKB:
FA5_HUMAN (P12259)
Ensembl:
ENSG00000198734
GenAtlas:
F5
GeneCard:
GC01M169481 (2153)
MutDB:
F5
ALFRED:
LO000606M
HuGE:
F5
Comparative Toxicogenomics Database:
2153
ModBase:
P12259
HGNC:
3542

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.